Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from GSK

Why Did FDA Pull Authorization For GSK-Vir's COVID-19 Therapy? Read Here

The U.S. health regulator said GlaxoSmithKline Plc (NYSE:GSK) and Vir Biotechnology Inc's (NASDAQ:VIR) antibody therapy was no longer authorized as a COVID-19 treatment. The decision was made as the CDC now estimates that the proportion of Covid-19 cases caused by BA.2 is above 50% nationwide. "Sotrovimab is no longer authorized to treat COVID-19 in any…

Benzinga

Governments want COVID vaccine developers to aim higher in hunt for better shots

As governments prepare to live with COVID-19, some are questioning how much to rely on drugmakers to adapt vaccines to ward off future virus variants amid signs of tension between companies and regulators over the best approach, according to several sources familiar with the matter.

Reuters

CureVac - GSK Start Dosing In Next-Gen COVID-19 Vaccine Candidate Trial

CureVac N.V. (NASDAQ:CVAC) dosed the first participant in a Phase 1 study of COVID-19 second-generation mRNA vaccine candidate, CV2CoV, developed with GlaxoSmithKline plc (NYSE:GSK). The clinical trial is expected to provide valuable data to evaluate further the performance of CureVac’s second-generation mRNA backbone, which has the potential to be applied broadly in future vaccines against…

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

EMA Starts Review Of Sanofi-GlaxoSmithKline's COVID-19 Vaccine

The European Medicines Agency has started reviewing Sanofi SA (NASDAQ:SNY) and its partner GlaxoSmithKline Plc's (NYSE:GSK) application seeking conditional authorization for their COVID-19 vaccine. The vaccine candidate, Vidprevtyn, was already being evaluated under a rolling review by EMA. The drugmakers had earlier said that they would seek regulatory approval for their COVID-19 vaccine to be…

Benzinga

FDA Approves ViiV Healthcare's Cabenuva For Virologically Suppressed Adolescents With HIV

The FDA has approved ViiV Healthcare's Cabenuva (cabotegravir, rilpivirine) for HIV-1 in virologically suppressed adolescents. The approval covers patients aged 12 years or older and weighing at least 35kg on a stable antiretroviral regimen, with no history of treatment failure and no known or suspected resistance to either cabotegravir or rilpivirine. The regimen…

Benzinga

FDA Says Current Dose Of GSK-Vir's COVID-19 Therapy Unlikely To Work Against Omicron Subvariant

The FDA said that the currently authorized 500mg dose of GlaxoSmithKline Plc (NYSE:GSK) and Vir Biotechnology Inc's (NASDAQ:VIR) COVID-19 antibody therapy is unlikely to be effective against the omicron BA.2 variant. The agency updated its website to exclude sotrovimab use in geographic regions where the infection is likely caused by the omicron BA.2 variant. GSK…

Benzinga

KTR showcases Telangana to pharma majors

Meets top leadership of Pfizer, Johnson & Johnson and GSK as part of his official tour to the US

The Hindu

Read news from The Economist, FT, and more,
with one subscription

LifeMine Therapeutics, GSK Ink $70M Drug Discovery, Development Pact

LifeMine Therapeutics Inc, a drug discovery startup that uses genetically-encoded small molecules, has partnered with GlaxoSmithKline plc (NYSE:GSK) to discover and develop drugs from fungal genomes. GSK will bring three targets for LifeMine to run through its proprietary drug discovery platform, which scans for fungi that could be a match to create a…

Benzinga

Workers at GSK to vote on possible strike action over pay offer

Around 150 workers at the company's plant in Barnard Castle have rejected a 4% pay offer

Birmingham Post

GlaxoSmithKline says it will not start any new clinical trials in Russia

Pharma firm joins AstraZeneca and Pfizer in saying it will not enrol new patients into studies

The Guardian - UK

GSK halts new clinical trials in Russia but continues supply of medicines

The company is the latest drug-maker to take such steps, although the healthcare sector has not pulled out of the region entirely.

The Independent UK

Europe Kickstarts Reviewing AstraZeneca Application For Its COVID Antibody

European Medicines Agency has started reviewing AstraZeneca Plc's (NASDAQ:AZN) application for antibody-based COVID-19 therapy but gave no timeline for a conclusion. Infections from COVID-19 are still rising in parts of the world, including Europe. On Tuesday, China posted a steep jump in daily COVID-19 infections, with new cases more than doubling from a…

Benzinga

GSK/Vir Biotech's COVID-19 Antibody Associated With Resistance Mutations, New Research Shows

According to new research in Australia, some people have developed sotrovimab-resistant mutations following infusions with the GlaxoSmithKline Plc (NYSE:GSK) and Vir Biotechnology Inc (NASDAQ:VIR) monoclonal antibody with COVID-19 infection. Data shows that the mutations have been associated with a reduction by a factor of 100 to 297 in neutralization by sotrovimab. "These data show the persistence…

Benzinga

BP and Shell lead rush to exit Russia. There can be no going back

Oil is always a political business, and there’s no point pretending otherwise

The Guardian - UK

Get all your
news in one place.

100’s of premium titles.
One news app.

The Guardian - UK

GSK boss upbeat over spin-off of consumer healthcare unit

Expected to be the biggest London listing in a decade, the Haleon demerger is scheduled for July

Benzinga

GSK Stops Additional Three Respiratory Virus Vaccine Trials In Pregnant Women

GlaxoSmithKline Plc (NYSE: GSK) has halte

Asharq Al-Awsat

GSK Halts 3 Trials of Respiratory Virus Vaccine in Pregnant Women

Britain's GSK said on Monday it had halted enrollment and vaccination in three trials of its experimental vaccine against the respiratory syncytial virus (RSV) in pregnant women, the latest setback in developing a vaccine for the microbe. GSK said on Feb.

The Guardian - UK

Russian central bank hikes rates and closes stock market as rouble crashes; oil and gas soar – as it happened

Commodities including wheat and aluminium surge and European stocks slide as markets respond to wider sanctions on Russia

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Does CBD Have To Be Water Soluble? One Group Of Scientists Say Yes For Better Absorption

Several former scientists and staff from companies like Johnson & Johnson (NYSE: JNJ), GlaxoSmithKline (NYSE: GSK) and Schiff Nutrition are bringing a new delivery platform to market that boosts the bioavailability of&

Benzinga

AstraZeneca, GSK's COVID-19 Therapies Lose Efficacy Against Omicron's Subvariants

The FDA authorized an increased dose in the case of AstraZeneca Plc's (NASDAQ:

Benzinga

Canada Approves First Plant-Based COVID-19 Vaccine

As Sanofi SA (NASDAQ: SNY) and GlaxoSmithKline Plc's (NYSE: GSK) COVID-19 vaccine finally heads to regulators, another shot using GSK's pandemic adjuvant has

StockNews.com

5 Defensive Stocks to Own for Consistent Dividends and Stable Earnings

Concerns over the Russia-Ukraine war and high inflation have significantly affected the global equity markets lately. As the stock market is expected to remain highly volatile in the coming weeks, it could be wise to bet on defensive stocks Walmart (WMT), Novartis (NVS), Merck & Co. (MRK), GlaxoSmithKline (GSK), and…

Benzinga

Sanofi-GSK Prepare Regulatory Filings For COVID-19 Vaccine After Booster Data

Sanofi SA (NASDAQ: SNY) and GlaxoSmithKline plc (NYSE: GSK) are

The Guardian - UK

Sanofi and GSK seek approval for Covid-19 vaccine

The drugmakers hope to catch up with rivals after reporting positive results from late-stage clinical trials

The Guardian - UK

GSK unveils its new consumer brands spin-off name: Haleon

Products such as Voltaren, Sensodyne and Panadol to regroup under new stock market listing in summer

1 … 12 13 14 15

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

World Health Organization

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.